<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633046</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14224049</org_study_id>
    <nct_id>NCT02633046</nct_id>
  </id_info>
  <brief_title>Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS</brief_title>
  <acronym>PODOCYTE</acronym>
  <official_title>Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A 2 Part Prospective Study of H.P. Acthar® Gel (PODOCYTE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, multiple dose study to examine the effect of H.P. Acthar® Gel (repository
      corticotropin injection) in adult subjects with idiopathic focal segmental glomerulosclerosis
      (FSGS) who have failed to achieve remission with, or who are intolerant of, 1 or more
      previous immunosuppressive therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete and partial remission of proteinuria at Week 24.</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Number of subjects with complete remission (uPCR ≤ 300 mg/g) + number of subjects with partial remission (uPCR ≤ 3500 mg/g but &gt;300 mg/g and 50% reduction from baseline) at Week 24 (Visit 8)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Idiopathic Focal Segmental Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Acthar 80 U 3x/week Open Label Treatment Period</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Starting at Week 0-23, open label treatment with Acthar 80 U 3x/week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acthar 80 U 2x/week</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Starting at Week 26 for subjects who meet remission criteria at Week 23.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 80 U 2x/week</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Starting at Week 26 for subjects who meet remission criteria at Week 23.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acthar 80 U 3x/week Open Label Extension</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Starting at Week 26 for subjects who do not achieve remission at Week 23, an additional 24 weeks of open label treatment with Acthar 80 U 3x/week will be available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar 80 U 2x/week</intervention_name>
    <description>Acthar 80 U 2x/week</description>
    <arm_group_label>Acthar 80 U 2x/week</arm_group_label>
    <other_name>H.P. Acthar® Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo 80 U 2x/week</intervention_name>
    <description>Placebo 80 U 2x/week</description>
    <arm_group_label>Placebo 80 U 2x/week</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar 80 U 3x/week</intervention_name>
    <description>Acthar 80 U 3x/week</description>
    <arm_group_label>Acthar 80 U 3x/week Open Label Treatment Period</arm_group_label>
    <arm_group_label>Acthar 80 U 3x/week Open Label Extension</arm_group_label>
    <other_name>H.P. Acthar® Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subjects must meet all of the following criteria for inclusion in the study at the
        Screening Visit/Visit 1 and the Baseline Visit/Visit 2:

          1. Must be adequately informed and understand the nature and risks of the study and must
             be able to provide a signature and date on the ICF.

          2. Must be at least 18 years of age at Screening Visit/Visit 1 and can be male or female.

          3. Female subjects must be of nonchildbearing potential (history of hysterectomy,
             bilateral oophorectomy, or are postmenopausal with no history of menstrual flow in the
             12 months prior to Screening Visit/Visit 1), or if of childbearing potential must be
             nonpregnant, nonlactating and agree to use effective contraception with a male partner
             throughout study participation and for 4 weeks after ending study participation.
             Acceptable forms of contraception include hormonal measures (oral contraceptive pills,
             contraceptive patch, contraceptive ring, injections), intrauterine devices, double
             barrier method (condom plus diaphragm, condom or diaphragm plus spermicidal gel or
             foam), and abstinence.

          4. Must have a history of primary FSGS confirmed by a renal biopsy.

          5. Must be willing to undergo a renal biopsy unless the most recent renal biopsy is
             within 3 years of the Screening Visit/Visit 1.

          6. Must have a total urine protein creatinine ratio (uPCR) greater than 3.0 mg/mg at
             Screening Visit/Visit 1.

          7. Must have an estimated glomerular filtration rate (eGFR) at least 30 mL/min/1.73 m2 at
             the Screening Visit/Visit 1 as calculated by the 4-variable modification of diet in
             renal disease (MDRD) study equation.

          8. Must have failed to achieve sustained CR or PR of proteinuria as determined by the
             investigator with at least 1 prior immunosuppressive therapy, or must have intolerance
             to at least 1 prior immunosuppressive therapy.

          9. Must have been treated with an angiotensin converting enzyme inhibitor (ACEi) or
             angiotensin receptor blocker (ARB) for at least 4 weeks prior to Screening Visit/Visit
             1 and on stable maintenance dose(s) for at least 14 days prior to Screening
             Visit/Visit 1 and are expected to remain on that dose for the duration of the study or
             have a documented intolerance to ACEi or ARB with approval from the MM prior to
             enrollment. Subjects taking other antihypertensive medication(s), must be on a stable
             dose of for at least 4 weeks prior to the Screening Visit/Visit 1.

         10. Must have a mean systolic blood pressure no more than 150 mm Hg and a diastolic blood
             pressure of no more than 90 mm Hg determined by the average of at least 3 seated
             readings taken at least 5 minutes apart at Screening Visit/Visit 1 and at the Baseline
             Visit/Visit 2.

         11. Must be able to communicate effectively with study personnel.

         12. Must be able and willing to follow all protocol requirements and study restrictions.

         13. Must be able and willing to return for all study visits.

        Exclusion Criteria

        Subjects are ineligible for study participation if they meet any of the following criteria
        at the Screening Visit/Visit 1 or Baseline Visit/Visit 2:

          1. Is from a vulnerable population, as defined by the US CFR Title 45, Part 46, Section
             46.111(b) and other local and national regulations, including but not limited to,
             employees (temporary, part-time, full time, etc) or a family member of the research
             staff conducting the study, or of the sponsor, or of the clinical research
             organization, or of the IRB/IEC.

          2. Is unwilling to receive, or is intolerant of, subcutaneous injections.

          3. Has any history of use of ACTH preparations for treatment of nephrotic syndrome
             (including but not limited to Acthar and Synacthen®).

          4. Has a history of sensitivity to ACTH preparations (including but not limited to Acthar
             and Synacthen).

          5. Has a history of sensitivity to porcine protein products.

          6. Has a body mass index (BMI) greater than 45 kg/m2 at Screening Visit/Visit 1.

          7. Has secondary FSGS, including but not limited to, obesity, known genetic cause,
             reduced kidney mass, Human Immunodeficiency Virus (HIV), intravenous heroin abuse, or
             sickle cell anemia.

          8. Cannot have failed to achieve sustained CR or PR of proteinuria, as determined by the
             investigator, on more than 2 prior immunosuppressive therapies with different
             mechanisms of action.

          9. Has had a renal biopsy demonstrating greater than 50% global glomerular sclerosis, or
             greater than 50% cortical interstitial fibrosis, or collapsing FSGS.

         10. Has any known contraindication(s) to Acthar including, but not limited to:

         11. Any known history of scleroderma, osteoporosis, or ocular herpes simplex.

         12. Any current uncontrolled hypertension, primary adrenocortical insufficiency, or
             adrenal cortical hyperfunction.

         13. Any current congestive heart failure (defined as New York Heart Association Functional
             Class III to IV).

         14. Peptic ulcer (within 6 months prior to Screening Visit/Visit 1).

         15. Recent major surgery (within 6 months prior to Screening Visit/Visit 1, renal biopsy
             is not considered an exclusionary surgical procedure).

         16. Has a history of chronic active hepatitis; acute or chronic hepatitis B; or acute or
             chronic hepatitis C.

         17. Has a history of tuberculosis (TB) infection, any signs/symptoms of TB, or any close
             contact with an individual with an active TB infection.

         18. Has a clinically significant infection requiring intravenous administration of
             antibiotics and hospitalization in the 4 weeks prior to Screening Visit/Visit 1.

         19. Has known immune compromised status, including but not limited to, individuals who
             have undergone organ transplantation or who are known to be positive HIV.

         20. Has Type 1 or Type 2 diabetes mellitus (prior diagnosis of gestational diabetes
             mellitus is not exclusionary).

         21. Has had any of the following in the 12 weeks prior to Screening Visit 1/Visit 1:
             unstable angina confirmed by a cardiologist, myocardial infarction, coronary artery
             bypass graft, percutaneous trans-luminal coronary angioplasty, transient ischemic
             attack or cerebrovascular disease, unstable cardiac arrhythmia, or resuscitated sudden
             cardiac death.

         22. Has any solid tumor malignancy currently diagnosed or undergoing therapy, or has
             received therapy for any solid tumor malignancy in the 5 years prior to Screening
             Visit/Visit 1, with the exception of treated and cured basal cell carcinoma, treated
             and cured squamous cell carcinoma of the skin, and treated and cured carcinoma in situ
             of the cervix.

         23. Has a diagnosis of, is undergoing therapy for, or has received therapy for a
             hematologic malignancy in the 5 years prior to Screening Visit/Visit 1.

         24. Has been treated with certain medications within specified timeframes prior to the
             Screening Visit/Visit 1 (Rituximab, Investigational treatment for FSGS,
             Intravenous/intramuscular corticosteroids,Therapeutic drug/device trial (except FSGS),
             Cyclophosphamide, Chronic oral, corticosteroids

         25. Has been treated with certain medications within specified timeframes prior to
             Baseline Visit/Visit 2 (Corticosteroids , Mycophenolate, Mofetil).

         26. Has current or recent (within 6 months of the Screening Visit/Visit 1) drug or alcohol
             abuse as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth
             Edition, Diagnostic Criteria for Drug and Alcohol Abuse.

         27. Has any of the following laboratory abnormalities at the Screening Visit/Visit 1:

               -  Hemoglobin less than 8.0 g/dL.

               -  Platelets less than 50,000 cells/μL.

               -  Absolute neutrophil count (ANC) greater than 1000 cells/μL.

               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total
                  bilirubin greater than 2 times the upper limit of normal (ULN).

               -  Glycosylated hemoglobin (HbA1c) greater than 6.5%.

               -  Positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody
                  (HBcAb).

               -  Positive Hepatitis C virus antibody (HCV) and HCV polymerase chain reaction (PCR)
                  at least 25 IU/mL (HCV PCR will be automatically analyzed if HCV is positive).

               -  Positive or indeterminate interferon gamma release assay (IGRA).

         28. Has any other clinically significant disease, disorder or laboratory abnormality
             which, in the opinion of the investigator (by its nature or by being inadequately
             controlled), might put the patient at risk due to participation in the study, or may
             influence the results of the study or the subject's ability to complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leonor Nazareno</last_name>
    <phone>800-556-3314</phone>
    <email>clinicaltrials@mnk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Services, LLC</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Services, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kidney Disease Medical Group, Inc.</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kidney Disease Medical Group, Inc.</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academic Medical Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>VERITAS Research Corp</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocean Blue Medical Research</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Orlando VA Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Genesis Clinical Research Corp</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>GA Nephrology</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NANI Research</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville Research Foundation, Inc.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation, Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation, New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Washington Nephrology Associates</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>NKDHC Medical Research Services, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMC Nephrology Group</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Scott Research Inc</name>
      <address>
        <city>Laurelton</city>
        <state>New York</state>
        <zip>11413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine-Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metrolina Nephrology Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastern Nephrology Associates</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brookview Hills Research Associates, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians Company, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Knoxville Kidney Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Kidney Institute (Neprhotex Research Group)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington Nephrology Associates</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Virginia Nephrology Group (IntegraTrials, LLC)</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Wisconsin Dialysis Institute</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Renal Junín SRL</name>
      <address>
        <city>Junín</city>
        <state>BA</state>
        <zip>B6000GPB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Médicas</name>
      <address>
        <city>Mar del Plata</city>
        <state>BA</state>
        <zip>B7600FYK</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Hemodiálisis Temperley</name>
      <address>
        <city>Temperley</city>
        <state>BA</state>
        <zip>B1834MOD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Córdoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Privado de Especialidades Medicas-Fundación J. Robert Cade</name>
      <address>
        <city>Córdoba</city>
        <zip>X5003DDZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Renal Research Group</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospita</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Launceston Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunshine Hopital - Western Health</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernán Henríquez Aravena</name>
      <address>
        <city>Temuco</city>
        <state>IX Region</state>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Salvador</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>7500922</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Davila</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>8340518</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de la Universidad de Chile</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>8380456</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigación Nefrológica SC</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital y Clínica OCA S.A de C.V</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Cayetano Heredia</name>
      <address>
        <city>San Martin de Porres</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Arzobispo Loayza</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pavia Research Center/Nefrologia Asociacion de Santurce</name>
      <address>
        <city>San Juan</city>
        <zip>00909-2244</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Şişli Etfal Hamidiye Training and Research Hospital</name>
      <address>
        <city>İstanbul</city>
        <state>Sisli</state>
        <zip>034360</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>İstanbul University Faculty of Medicine</name>
      <address>
        <city>İstanbul</city>
        <state>Topkapi</state>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cukurova University Faculty of Medicine</name>
      <address>
        <city>Adana</city>
        <zip>1130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ankara NumuneTraining and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ankara Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>İstanbul University Faculty of Medicine</name>
      <address>
        <city>İstanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kocaeli University Faculty of Medicine</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marmara University Faculty of Medicine</name>
      <address>
        <city>Maltepe</city>
        <zip>34840</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mersin University Faculty of Medicine</name>
      <address>
        <city>Mersin</city>
        <zip>33000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Hong Kong</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FSGS</keyword>
  <keyword>primary FSGS</keyword>
  <keyword>idiopathic FSGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

